Let's see what awaits Aussie investors during today's session. The post 5 things to watch on the ASX 200 on Tuesday appeared ...

Bell Potter notes that Neuren has released an update on Acadia's sales and its expected royalties. It said: ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Australian shares are due to fall at the open, even as Wall Street stocks ended higher, buoyed by another slate of ...

Biotech group Neuren Pharmaceuticals has reported a 14% uptick in quarterly US sales of its Retts syndrome treatment Daybue.

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Dual-listed across the Nasdaq composite and the ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as sales of its flagship drug DAYBUE jump +14% on Q2 2024. Listen ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

Aug 2025 - Acadia Pharmaceuticals reports a 14% increase in DAYBUE™ net sales, boosting Neuren's royalty income.